EP3580335A1 - Lipases présentant une meilleure stabilité à la température - Google Patents
Lipases présentant une meilleure stabilité à la températureInfo
- Publication number
- EP3580335A1 EP3580335A1 EP18703258.6A EP18703258A EP3580335A1 EP 3580335 A1 EP3580335 A1 EP 3580335A1 EP 18703258 A EP18703258 A EP 18703258A EP 3580335 A1 EP3580335 A1 EP 3580335A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- lipase
- amino acid
- seq
- positions
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090001060 Lipase Proteins 0.000 title claims abstract description 195
- 239000004367 Lipase Substances 0.000 title claims abstract description 194
- 102000004882 Lipase Human genes 0.000 title claims abstract description 194
- 235000019421 lipase Nutrition 0.000 title claims abstract description 194
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 95
- 238000006467 substitution reaction Methods 0.000 claims abstract description 71
- 238000004140 cleaning Methods 0.000 claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 52
- 150000001413 amino acids Chemical class 0.000 claims description 42
- 150000007523 nucleic acids Chemical class 0.000 claims description 38
- 238000005406 washing Methods 0.000 claims description 37
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 102200164348 rs41295282 Human genes 0.000 claims description 19
- 239000012459 cleaning agent Substances 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 14
- 239000004753 textile Substances 0.000 claims description 14
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 238000002703 mutagenesis Methods 0.000 claims description 9
- 231100000350 mutagenesis Toxicity 0.000 claims description 9
- 238000013467 fragmentation Methods 0.000 claims description 7
- 238000006062 fragmentation reaction Methods 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 3
- 239000013599 cloning vector Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 description 79
- 210000004027 cell Anatomy 0.000 description 51
- 108090000623 proteins and genes Proteins 0.000 description 45
- 102000004190 Enzymes Human genes 0.000 description 43
- 108090000790 Enzymes Proteins 0.000 description 43
- 229940088598 enzyme Drugs 0.000 description 43
- 102000004169 proteins and genes Human genes 0.000 description 43
- 229940024606 amino acid Drugs 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 39
- 239000003599 detergent Substances 0.000 description 35
- 230000000694 effects Effects 0.000 description 20
- 239000007788 liquid Substances 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000000855 fermentation Methods 0.000 description 12
- 230000004151 fermentation Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000002255 enzymatic effect Effects 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 101000966369 Rhizopus oryzae Lipase Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- -1 Example Chemical class 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000002366 lipolytic effect Effects 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002689 soil Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- 240000005384 Rhizopus oryzae Species 0.000 description 3
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004851 dishwashing Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 235000019626 lipase activity Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 102100032487 Beta-mannosidase Human genes 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010059820 Polygalacturonase Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 241000122971 Stenotrophomonas Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 108010055059 beta-Mannosidase Proteins 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 108010093305 exopolygalacturonase Proteins 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 238000010297 mechanical methods and process Methods 0.000 description 2
- 230000005226 mechanical processes and functions Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002887 multiple sequence alignment Methods 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000203809 Actinomycetales Species 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193375 Bacillus alcalophilus Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 241001328119 Bacillus gibsonii Species 0.000 description 1
- 241000006382 Bacillus halodurans Species 0.000 description 1
- 241000193422 Bacillus lentus Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000223198 Humicola Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000185994 Pseudarthrobacter oxydans Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000588746 Raoultella planticola Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191965 Staphylococcus carnosus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000002979 fabric softener Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 108010038851 tannase Proteins 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 108010083879 xyloglucan endo(1-4)-beta-D-glucanase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
Definitions
- the invention is in the field of enzyme technology.
- the invention relates to lipases from Rhizopus oryzae whose amino acid sequence, in particular with regard to the use in detergents and cleaning agents have been changed to give them a better thermal stability, and encoding them for nucleic acids and their preparation.
- the invention further relates to the uses of these lipases and processes in which they are used as well as agents containing them, in particular washing and cleaning agents.
- Lipases are among the most technically important enzymes of all. Their use in detergents and cleaning agents is industrially established and they are contained in virtually all modern, powerful detergents and cleaners. Lipases are enzymes that catalyze the hydrolysis of ester bonds in lipid substrates, especially in fats and oils, and thus belong to the group of esterases. Lipases are typically enzymes that can cleave a variety of substrates, for example, aliphatic, alicyclic, bicyclic and aromatic esters, thioesters and activated amines. Lipases are used to remove greasy soils by catalyzing their hydrolysis (lipolysis).
- Lipases with broad substrate spectra are used in particular where inhomogeneous raw materials or substrate mixtures have to be reacted, for example in detergents and cleaners, since soiling may consist of differently structured fats and oils.
- the lipases used in the washing or cleaning agents known from the prior art are usually of microbial origin and are generally derived from bacteria or fungi, for example the genera Bacillus, Pseudomonas, Acinetobacter, Micrococcus, Humicola, Trichoderma or Trichosporon. Lipases are usually produced by biotechnological methods known per se by suitable microorganisms, for example by transgenic expression hosts of the genera Bacillus or by filamentous fungi.
- European patent application EP 443063 describes a lipase from Pseudomonas sp. Intended for washing and cleaning agents. ATCC 21808.
- Japanese Patent Application JP 1225490 discloses a Rhizopus oryzae lipase.
- only selected lipases are suitable for use in liquid surfactant-containing preparations. Many lipases do not show sufficient catalytic performance or stability in such formulations.
- washing processes which are generally carried out at temperatures higher than 20 ° C, many lipases show thermal instability, which in turn leads to insufficient catalytic activity during the washing process.
- this problem is even more serious, for example - -
- lipase and surfactant-containing liquid formulations of the prior art have the disadvantage that they often do not have satisfactory lipolytic activity in the temperature ranges required by a washing process and therefore do not show optimum cleaning performance on lipase-sensitive soils.
- a lipase from Rhizopus oryzae or a sufficiently similar lipase which has an amino acid substitution at least one of the positions S93, P145, L156, K169, N193, G202, Q225, K235, V236, P260, H298, P308, F31 1, N328, L352, D359 or S364 in each case based on the numbering according to SEQ ID NO: 1, is improved in terms of the (thermal) stability compared to the wild-type form and therefore particularly suitable for use in Washing or cleaning agents is suitable.
- the invention therefore in a first aspect comprises a lipase comprising an amino acid sequence which has at least 70% sequence identity with the amino acid sequence given in SEQ ID NO: 1 over its entire length and an amino acid substitution at at least one of the positions S93, P145, L156, K169, N193, G202, Q225, K235, V236, P260, H298, P308, F31 1, N328, L352, D359 or S364 in each case based on the numbering according to SEQ ID NO: 1.
- the lipase has an amino acid substitution at position H298, most preferably the amino acid substitution H298N.
- the lipase in addition to the amino acid substitution at position 298, has at least one additional amino acid substitution at one of the positions S93, P145, L156, K169, N193, G202, Q225, K235, V236, P260, H298, P308 , F31 1, N328, L352, D359 or S364.
- amino acid substitution selected from the group consisting of S93G, P145L, L156P, K169E, N193E, G202V, Q225H, K235N, V236M, P260S, H298N, P308S, P308T, F31 1Y, N328D, L352T, D359G, and S364F, respectively the numbering according to SEQ ID NO: 1.
- the lipase has at least two amino acid substitutions at the positions H298 and S364, particularly preferred are the amino acid substitutions H298N and S364F, each based on the numbering according to SEQ ID NO: 1.
- Another object of the invention is a process for the preparation of a lipase comprising the substitution of an amino acid at least one position, the position S93, P145, L156, K169, N193, G202, Q225, K235, V236, P260, H298, P308, F31 1, N328, L352, D359 or - -
- Preferred is a method of producing a lipase comprising substituting an amino acid at least at the position H298, more preferably the amino acid substitution is H298N.
- a lipase in the sense of the present patent application therefore comprises both the lipase as such and a lipase produced by a method according to the invention. All statements on the lipase therefore relate both to the lipase as such and to the lipases produced by means of corresponding processes.
- nucleic acids coding for these lipases relate to the nucleic acids coding for these lipases, non-human host cells according to the invention containing lipases or nucleic acids, and in particular detergents and cleaning agents, washing and cleaning processes, and uses of the lipases according to the invention in detergents or cleaners for the removal of greasy soiling.
- At least one as used herein means one or more, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more.
- the present invention is based on the surprising discovery of the inventors that an amino acid substitution at at least one of the positions 93, 145, 156, 169, 193, 202, 225, 235, 236, 260, 298, 308, 31 1, 328, 352, 359 or 364 of the Rhizopus oryzae lipase according to SEQ ID NO: 1, in a lipase comprising at least 70% identical amino acid sequence to the amino acid sequence given in SEQ ID NO: 1, such that at least one of the corresponding positions contains the amino acids S93, P145, L156, K169, N193, G202, Q225, K235, V236, P260, H298, P308, F31 1, N328, L352, D359 or S364, improved (thermal) stability of this altered lipase in washing and Detergents causes.
- This is particularly surprising inasmuch as none of the abovementioned amino acid substitutions has been previously associated with increased stability of the lipase. - -
- the lipases according to the invention have increased stability in detergents or cleaners, in particular to elevated temperatures. Such performance-enhanced lipases provide improved wash results on lipolytically-sensitive soils over a wide temperature range.
- the lipases according to the invention have enzymatic activity, that is, they are capable of hydrolysing fats and oils, in particular in a washing or cleaning agent.
- a lipase of the invention is therefore an enzyme which catalyzes the hydrolysis of ester bonds in lipid substrates and thereby is able to cleave fats or oils.
- a lipase of the invention is preferably a mature lipase, i. to the catalytically active molecule without signal and / or propeptide (s). Unless otherwise stated, the sequences given refer to each mature (processed) enzymes.
- the lipase of the present invention contains at least one amino acid substitution selected from the group consisting of S93G, P145L, L156P, K169E, N193E, G202V, Q225H, K235N, V236M, P260S, H298N, P308S, P308T, F31 1Y, N328D, L352T, D359G and S364F, each based on the numbering according to SEQ ID NO: 1, is selected.
- the lipase of the invention contains one of the following amino acid substitution variants: (i) P145L, P260S and H298N; (ii) V236M; (iii) F31 1Y and D359G; (Iv) K169E; (V) K235N; (vi) S93G, G202V and P308Q; (vii) H298N; (viii) P145L, P260S, H298N and L156P; (ix) P145L, P260S, H298N and S364F; (x) P145L, P260S, H298N and Q225H; (xi) P145L, P260S, H298N and P308S; (xii) P145L, P260S, H298N and N328D; (xiii) H298N and L156P; (xiv) H298N and S364F; (xv) H298N and Q225H; (xi) P145L
- the variants containing substitution at position 298, particularly 298N are preferred. Further, those having no substitutions at positions 145 and 260 are particularly preferred. Most preferred are those having a substitution at position 298, especially 298N, and at least one substitution at one of positions 156, 225, 308, 328 or 364, but none at positions 145 and 260. More particularly, those mentioned above Variants (xiv) to (xx).
- the lipase comprises an amino acid sequence which corresponds to the amino acid sequence given in SEQ ID NO: 1 over its total length to at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77 %, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 90, 91, 91 , 5%, 92%, 92.5%, 93%, 93.5%, 94%, 94.5%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5 %, 98%, 98.5% and 98.8%, and at least one of the positions 93, 145, 156, 169, 193, 202, 225, 235, 236, 260, 298, 308, 31 1 , 328, 352, 359 or 364 in the count according to SEQ ID NO. 1 has one or more of the amino acid substitutions, in particular at least one
- the feature means that a lipase has the indicated substitutions that it contains at least one of the corresponding amino acids at the corresponding positions, i. not all of the 13 positions are otherwise mutated or deleted, for example by fragmentation of the lipase.
- the amino acid sequences of such lipases which are preferred according to the invention, are given in SEQ ID Nos: 2-21.
- sequence comparison is based on the BLAST algorithm established and commonly used in the prior art (see, for example, Altschul, SF, Gish, W., Miller, W., Myers, EW & Lipman, DJ. (1990) "Basic local alignment search Biol. 215: 403-410; and Altschul, Stephan F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Hheng Zhang, Webb Miller, and David J.
- Lipman (1997): "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs"; Nucleic Acids Res., 25, pp.3389-3402) and is in principle effected by similar sequences of nucleotides or amino acids in the nucleic acid or nucleic acid sequences Amino acid sequences are assigned to each other. A tabular assignment of the respective positions is referred to as alignment.
- Another algorithm available in the prior art is the FASTA algorithm. Sequence comparisons (alignments), in particular multiple sequence comparisons, are created with computer programs.
- the Clustal series see, for example, Chenna et al., 2003: Multiple sequence alignment with the Clustal series of programs, Nucleic Acid Research 31, 3497-3500
- T-Coffee see, for example, Notredame et al (2000): T-Coffee: A novel method for multiple sequence alignments, J. Mol. Biol. 302, 205-217
- programs based on these programs or algorithms are also possible.
- alignment comparisons with the computer program Vector NTI® Suite 10.3 (Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California, USA) with the default parameters, whose AlignX module for sequence comparisons is based on ClustalW.
- the sequence identity given herein is determined by the BLAST algorithm.
- Such a comparison also allows a statement about the similarity of the compared sequences to each other. It is usually given in percent identity, that is, the proportion of identical nucleotides or amino acid residues at the same or in an alignment corresponding positions.
- the broader concept of homology involves conserved amino acid substitutions in the consideration of amino acid sequences, that is, amino acids with similar chemical activity, as these usually perform similar chemical activities within the protein. Therefore, the similarity of the sequences compared may also be stated as percent homology or percent similarity.
- Identity and / or homology information can be made about whole polypeptides or genes or only over individual regions. Homologues or Identical regions of different nucleic acid or amino acid sequences are therefore defined by matches in the sequences. Such areas often have identical functions.
- nucleic acid or amino acid sequence can be small and comprise only a few nucleotides or amino acids. Often, such small regions exert essential functions for the overall activity of the protein. It may therefore be useful to relate sequence matches only to individual, possibly small areas. Unless otherwise indicated, identity or homology information in the present application, however, refers to the total length of the particular nucleic acid or amino acid sequence indicated.
- the lipase is characterized in that its purification performance is not significantly reduced compared to that of a lipase comprising an amino acid sequence corresponding to the amino acid sequence given in SEQ ID NO: 1, i. has at least 80% of the reference washing power, preferably at least 100%, more preferably at least 1 10%.
- the cleaning performance can be determined in a washing system containing a detergent in a dosage between 4.5 and 7.0 grams per liter of wash liquor and the lipase, wherein the lipases to be compared are used in the same concentration (based on active protein) and the cleaning performance a soiling on cotton is determined by measuring the degree of cleaning of the washed textiles.
- the washing process for 70 minutes at a temperature of 40 ° C and the water have a water hardness between 15.5 and 16.5 ° (German hardness).
- the concentration of the lipase in the detergent intended for this washing system is 0.001-0.1% by weight, preferably 0.01-0.06% by weight, based on active, purified protein.
- a liquid reference detergent for such a washing system may be composed as follows (all figures in weight percent): 7% alkylbenzenesulfonic acid, 9% other anionic surfactants, 4% C12-C18 Na salts of fatty acids (soaps), 7% not ionic surfactants, 0.7% phosphonates, 3.2% citric acid, 3.0% NaOH, 0.04% defoamer, 5.7% 1, 2-propanediol, 0.1% preservatives, 2% ethanol, 0.2% dye transfer inhibitor, remainder demineralized water.
- the dosage of the liquid detergent is between 4.5 and 6.0 grams per liter of wash liquor, for example, 4.7, 4.9 or 5.9 grams per liter of wash liquor.
- the determination of the cleaning performance is carried out, for example, at 34.8 ° C using a liquid detergent as indicated above, wherein the washing process is preferably carried out for 30 minutes.
- the whiteness i. the brightening of the stains, as a measure of the cleaning performance is determined by optical measurement methods, preferably photometrically.
- a suitable device for this purpose is for example the spectrometer Minolta CM508d.
- the devices used for the measurement are previously calibrated with a white standard, preferably a supplied white standard.
- the activity-like use of the respective lipase ensures that even if the ratio of active substance to total protein (the values of the specific activity) diverge, the respective enzymatic properties, for example the cleaning performance of certain soils, are compared. In general, a low specific activity can be compensated by adding a larger amount of protein.
- the lipase activity can also be determined in the usual manner, preferably as described in Bruno Stellmach, "Methods of Determining Enzymes for Pharmacy, Food Chemistry, Technology, Biochemistry, Biology, Medicine” (Steinkopff Verlag Darmstadt, 1988, p 172ff)
- Lipase-containing samples are added to an olive oil emulsion in emulsifier-containing water and incubated at 30 ° C and pH 9.0, thereby fatty acids are released.These are titrated with an autotitrator over 20 minutes continuously with 0.01 N sodium hydroxide solution, so that the pH remains constant (“pH stat titration"). Based on the sodium hydroxide consumption, the determination of the lipase activity takes place by reference to a reference lipase sample.
- An alternative test for determining the lipolytic activity of the lipases according to the invention is an optical measurement method, preferably a photometric method.
- the appropriate test involves the lipase-dependent cleavage of the substrate para-nitrophenol butyrate (pNP-butyrate). This is cleaved by the lipase into para-nitrophenolate and butyrate.
- the presence of para-nitrophenolate can be measured using a photometer, e.g. of the Tecan Sunrise device and the XFLUOR software, at 405 nm, thus allowing a conclusion on the enzymatic activity of the lipase.
- the protein concentration can be determined by known methods, for example, the BCA method (bicinchoninic acid, 2,2'-biquinolyl-4,4'-dicarboxylic acid) or the biuret method (AG Gornall, CS Bardawill and MM David, J. Biol. Chem., 177 (1948), pp. 751-766). Determination of the active protein concentration in this regard may be achieved by titration of the active sites using a suitable irreversible inhibitor and determination of residual activity (see M. Bender et al., J. Am. Chem. Soc., 88, 24 (1966), p -5913).
- lipases according to the invention can undergo further amino acid changes, in particular amino acid substitutions, - -
- lipases are, for example, by targeted genetic modification, i. by mutagenesis, further developed and optimized for specific applications or specific properties (for example, in terms of catalytic activity, stability, etc.).
- nucleic acids according to the invention can be introduced into recombination approaches and thus used to generate completely novel lipases or other polypeptides.
- the goal is to introduce into the known molecules targeted mutations such as substitutions, insertions or deletions, for example, to improve the cleaning performance of enzymes of the invention.
- targeted mutations such as substitutions, insertions or deletions
- the surface charges and / or the isoelectric point of the molecules and thereby their interactions with the substrate can be changed.
- the net charge of the enzymes can be changed in order to influence the substrate binding, in particular for use in detergents and cleaners.
- the stability of the lipase can be further increased by one or more corresponding mutations, thereby improving its cleaning performance.
- Advantageous properties of individual mutations, e.g. individual substitutions can complement each other.
- a lipase which has already been optimized with regard to certain properties, for example with respect to its stability to elevated temperatures, can therefore be further developed within the scope of the invention.
- amino acid substitutions For the description of substitutions concerning exactly one amino acid position (amino acid substitutions), the following convention is used herein: first, the naturally occurring amino acid is designated in the form of the international one-letter code, followed by the associated sequence position and finally the inserted amino acid. Several exchanges within the same polypeptide chain are separated by slashes. For insertions, additional amino acids are named after the sequence position. In the case of deletions, the missing amino acid is replaced by a symbol, for example a star or a dash, or a ⁇ is specified in front of the corresponding position.
- H298N describes the substitution of histidine at position 298 with asparagine, H298HE the insertion of glutamic acid after the amino acid histidine at position 298 and H298 * or AH298 the deletion of histidine at position 298.
- This nomenclature is known to those skilled in the art of enzyme technology.
- Another object of the invention is therefore a lipase, which is characterized in that it is obtainable from a lipase as described above as the starting molecule by single or multiple conservative amino acid substitution, wherein the lipase in the count according to SEQ ID NO: 1 nor at least one the amino acid substitutions according to the invention at the positions corresponding to positions 93, 145, 156, 169, 193, 202, 225, 235, 236, 260, 298, 308, 31 1, 328, 352, 359 and 364 in SEQ ID NO: 1 , as described above.
- amino acid substitution means the replacement of an amino acid residue with a different amino acid residue, said exchange not resulting in a change in polarity or charge at the position of the exchanged amino acid, e.g. Example, the replacement of a nonpolar amino acid residue against another nonpolar amino acid residue.
- the lipase is characterized in that it is obtainable from a lipase according to the invention as starting molecule by fragmentation, deletion, insertion or substitution mutagenesis and comprises an amino acid sequence which is over a length of at least 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340 , 350, 360, 361, 362, 363, 364 or 365 contiguous amino acids with the parent molecule, wherein the (s) amino acid substitution (s) contained in the starting molecule at one or more of the positions, the positions 93, 145, 156, 169, 193, 202, 225, 235, 236, 260, 298, 308, 31 1, 328, 352, and 359 and 364 in SEQ ID NO: 1 are still present.
- the enzymes retain their lipolytic activity, i. their lipolytic activity is at least equal to that of the parent enzyme, i. in a preferred embodiment, the lipolytic activity is at least 80, preferably at least 90% of the activity of the starting enzyme.
- Other substitutions can also show beneficial effects. Both single and multiple contiguous amino acids can be substituted for other amino acids.
- the lipases of the present invention are characterized by being C-terminal fragments of the proteins described herein. Particular preference is given to those fragments which lack the N-terminal prosequence, ie the first 69 amino acids of the sequence according to SEQ ID NO: 1. All sequences described in the present application may be corresponding fragments lacking the amino acids corresponding to amino acids 1-69 of the lipase having the sequence shown in SEQ ID NO: 1. This is especially true for the mutants described herein having SEQ ID Nos. 2-21 too. The corresponding mature sequences to which the first 69 amino acids of the sequences according to SEQ ID Nos. 2-21 missing are also explicitly included here.
- the invention therefore also relates to lipases which contain amino acids 70-366 of the amino acid sequences according to SEQ ID Nos. 2-21 or consist of these. In various embodiments of the invention, therefore, it also detects lipases which have 70% sequence identity with amino acids 70-366 of the amino acid sequence given in SEQ ID NO: 1 and which have an amino acid substitution. On at least one of the positions S93, P145, L156, K169, N193, G202, Q225, K235, V236, P260, H298, P308, F31 1, N328, L352, D359 or S364 in each case based on the numbering according to SEQ ID NO: 1. All embodiments disclosed herein in the context of the lipases having the propeptide are also lacking the corresponding mature lipases lacking the propeptide corresponding sequence of amino acids 1-69 of SEQ ID NO: 1, transferable.
- variants that are C-terminally and / or N-terminally extended compared to the variants described herein, i. at the N- and / or C-terminus, for example, comprise 1 to 68 additional amino acids.
- N-terminally extended variants are, for example, the above-described variant variants of SEQ ID Nos. 2-21 polypeptide sequences (which include the AS 70-366), which still contain residues of the original 69 AS long prosequence.
- the lipase is characterized in that it is obtainable from a lipase according to the invention as starting molecule by one or more conservative amino acid substitution, the lipase containing at least one of the amino acid substitutions S93G, P145L, L156P, K169E, N193E, G202V, Q225H, K235N, V236M, P260S, H298N, P308S, P308T, F31 1Y, N328D, L352T, D359G and S364F at positions corresponding to positions 93, 145, 156, 169, 193, 202, 225, 235, 236, 260, 298, 308 , 31 1, 328, 352, and 359 and 364 as shown in SEQ ID NO: 1.
- the lipase is characterized in that it is obtainable from a lipase according to the invention as the starting molecule by fragmentation, deletion, insertion or substitution mutagenesis and comprises an amino acid sequence which is over a length of at least 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330 , 340, 350, 360 or 366 contiguous amino acids with the parent molecule, the lipase having at least one of the amino acid substitutions S93G, P145L, L156P, K169E, N193E, G202V, Q225H, K235N, V236M, P260S, H298N, P308S, P308T, F31 1Y , N328D, L352T, D359G and S364F at the positions
- the further amino acid positions are hereby defined by an alignment of the amino acid sequence of a lipase according to the invention with the amino acid sequence of the lipase from Rhizopus oryzae, as indicated in SEQ ID NO: 1. Furthermore, the assignment of the positions depends on the mature (mature) protein. This assignment should also be used in particular if the amino acid sequence of a lipase according to the invention comprises a higher number of amino acid residues than the Rhizopus oryzae lipase according to SEQ ID NO. 1. Based on the above positions in the amino acid sequence of the Rhizopus oryzae lipase, the changes are - - derungspositionen in a lipase according to the invention those who are just assigned to these positions in an alignment.
- Advantageous positions for sequence changes, in particular substitutions, of the Rhizopus oryzae lipase which are preferably transferred to homologous positions of the lipases according to the invention and which confer advantageous functional properties on the lipase, are accordingly the positions which are aligned in positions 93, 145, 156 , 169, 193, 202, 225, 235, 236, 260, 298, 308, 31 1, 328, 352, and 359 and 364 in SEQ ID NO: 1, ie in the counting according to SEQ ID NO: 1.
- Rhizopus oryzae lipase are the following amino acid residues: S93, P145, L156, K169, N193, G202, Q225, K235, V236, P260, H298, P308, F31 1, N328, L352, D359 or S364.
- an amino acid exchange in a specific position of the Rhizopus oryzae lipase according to SEQ ID NO: 1 is accompanied by a change in an enzymatic parameter, for example an increase in the M value
- a corresponding change in the enzymatic parameter for example likewise one Increasing the M value, observed in a lipase variant according to the invention, whose amino acid exchange has been achieved by the same amino acid introduced, is here to be seen confirmation of the correct assignment.
- a method according to the invention further comprises one or more of the following method steps: a) introducing a single or multiple conservative amino acid substitution, wherein the lipase at least one of the amino acid substitutions S93G, P145L, L156P, K169E, N193E, G202V, Q225H, K235N, V236M, P260S , H298N, P308S, P308T, F31 1Y, N328D, L352T, D359G and S364F at the positions corresponding to the positions 93, 145, 156, 169, 193, 202, 225, 235, 236, 260, 298, 308, 31 1 , 328, 352, 359 and 364 as shown in SEQ ID NO: 1; b) alteration of the amino acid sequence by fragmentation, deletion, insertion or substitution mutagenesis such that the lipase comprises an amino acid
- the lipase or the lipase produced by a method according to the invention is still at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80 %, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 90.5%, 91%, 91, 5%, 92%, 92, 5%, 93%, 93.5%, 94%, 94.5%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5% , or 98.8% identical to the amino acid sequence given in SEQ ID NO: 1 over its entire length.
- the lipase or the lipase prepared by a method according to the invention is still at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%. , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 90.5%, 91%, 91, 5%, 92%, 92.5%, 93 %, 93.5%, 94%, 94.5%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, or 98% identical to any one of SEQ ID Nos : 2-10 or 1-21 amino acid sequences over their entire length.
- the lipase or the lipase prepared by a method according to the invention has an amino acid substitution on at least one of the positions S93, P145, L156, K169, N193, G202, Q225, K235, V236, P260, H298, P308, F31 1, N328, L352, D359 or S364, each based on the numbering according to SEQ ID NO: 1, on.
- the amino acid substitution is at least one selected from the group consisting of S93G, P145L, L156P, K169E, N193E, G202V, Q225H, K235N, V236M, P260S, H298N, P308S, P308T, F31 1Y, N328D, L352T, D359G and S364F , in each case based on the numbering according to SEQ ID NO: 1.
- the lipase comprises one of the following amino acid substitution variants: (i) P145L, P260S and H298N; (ii) V236M; (iii) F31 1Y and D359G; (Iv) K169E; (V) K235N; (vi) S93G, G202V and P308Q; (vii) H298N; (viii) P145L, P260S, H298N and L156P; (ix) P145L, P260S, H298N and S364F; (x) P145L, P260S, H298N and Q225H; (xi) P145L, P260S, H298N and P308S; (xii) P145L, P260S, H298N and N328D; (xiii) H298N and L156P; (xiv) H298N and S364F; (xv) H298N and Q225H; (xvi) H
- Another object of the invention is a previously described lipase, which is additionally stabilized, in particular by one or more mutations, for example substitutions, or by coupling to a polymer.
- all stabilization options described in the prior art and / or appropriate considerations come into consideration. Preference is given to those stabilizations which are achieved via mutations of the enzyme itself, since such stabilization after the recovery of the enzyme no further - -
- Preferred embodiments are those in which the enzyme is stabilized in several ways, as several stabilizing mutations act additive or synergistic.
- Another object of the invention is a lipase as described above, which is characterized in that it has at least one chemical modification.
- a lipase with such a change is called a derivative, i. the lipase is derivatized.
- derivatives are understood as meaning those proteins whose pure amino acid chain has been chemically modified.
- derivatizations can be done, for example, in vivo by the host cell expressing the protein.
- couplings of low molecular weight compounds such as lipids or oligosaccharides are particularly noteworthy.
- derivatizations can also be carried out in vitro, for example by the chemical transformation of a side chain of an amino acid or by covalent binding of another compound to the protein.
- another compound may also be another protein that is bound to a protein of the invention via bifunctional chemical compounds, for example.
- derivatization is to be understood as meaning the covalent binding to a macromolecular carrier, or else a noncovalent inclusion in suitable macromolecular cage structures.
- Derivatizations may, for example, affect the substrate specificity or binding strength to the substrate or cause a temporary blockage of the enzymatic activity when the coupled substance is an inhibitor. This can be useful, for example, for the period of storage. Such modifications may further affect stability or enzymatic activity. They can also serve to reduce the allergenicity and / or immunogenicity of the protein and thus, for example, increase its skin compatibility.
- couplings with macromolecular compounds for example, polyethylene glycol, can improve the protein in terms of stability and / or skin tolerance.
- Derivatives of a protein according to the invention can also be understood in the broadest sense to mean preparations of these proteins.
- a protein may be combined with various other substances, for example from the culture of the producing microorganisms.
- a protein may also have been deliberately added to other substances, for example to increase its storage stability. Therefore, all preparations of a protein according to the invention are also according to the invention. This is also independent of whether or not it actually exhibits this enzymatic activity in a particular preparation. Because it may be desired that it has no or only low activity during storage, and unfolds its enzymatic function only at the time of use. This can be controlled, for example, via appropriate accompanying substances. In particular, the joint preparation of lipases with specific inhibitors is possible in this regard.
- lipases or lipase variants and / or derivatives described above particular preference is given in the context of the present invention to those whose stability and / or activity corresponds to at least one of the lipases according to SEQ ID Nos: 2-21, and / or their purification performance of at least one of them the lipases according to SEQ ID Nos: 2-21, wherein the cleaning performance is determined in a washing system as described above.
- a further subject of the invention is a nucleic acid which codes for a lipase according to the invention, as well as a vector containing such a nucleic acid, in particular a cloning vector or an expression vector.
- DNA or RNA molecules may be DNA or RNA molecules. They can be present as a single strand, as a single strand that is complementary to this single strand, or as a double strand. Especially in the case of DNA molecules, the sequences of both complementary strands must be taken into account in all three possible reading frames. Furthermore, it should be noted that different codons, so base triplets, can code for the same amino acids, so that a particular amino acid sequence can be encoded by several different nucleic acids. Due to this degeneracy of the genetic code, all nucleic acid sequences are included in this subject of the invention which can encode any of the lipases described above.
- nucleic acid sequences unequivocally since, despite the degeneracy of the genetic code, individual codons are assigned defined amino acids. Therefore, the person skilled in the art can easily determine nucleic acids coding for this amino acid sequence on the basis of an amino acid sequence.
- one or more codons may be replaced by synonymous codons.
- This aspect relates in particular to the heterologous expression of the enzymes according to the invention.
- each organism for example a host cell of a production strain, has a particular codon usage. Codon usage is understood to mean the translation of the genetic code into amino acids by the particular organism.
- a person skilled in the art can use well-known methods such as chemical synthesis or the polymerase chain reaction (PCR) in combination with molecular biological and / or proteinchemical standard methods, using known DNA and / or amino acid sequences, the corresponding nucleic acids to complete genes manufacture.
- PCR polymerase chain reaction
- Such methods are for example from Sambrook, J., Fritsch, E.F. and Maniatis, T. 2001. Molecular cloning: a laboratory manual, 3rd Edition Cold Spring Laboratory Press.
- vectors are understood as consisting of nucleic acids which contain a nucleic acid according to the invention as a characteristic nucleic acid region. They can establish these in a species or cell line over several generations or cell divisions as a stable genetic element.
- Vectors especially when used in bacteria, are special plasmids, ie circular genetic elements.
- a nucleic acid according to the invention is cloned into a vector.
- the vectors include, for example, those whose origin are bacterial plasmids, viruses or bacteriophages, or predominantly synthetic vectors or plasmids with elements of various origins. With the other genetic elements present in each case, vectors are able to establish themselves as stable units in the relevant host cells over several generations. They may be extrachromosomal as separate units or integrated into a chromosome or chromosomal DNA.
- Expression vectors comprise nucleic acid sequences which enable them to replicate in the host cells containing them, preferably microorganisms, particularly preferably bacteria, and to express a contained nucleic acid there.
- expression is influenced by the promoter (s) that regulate transcription.
- the expression may be effected by the natural promoter originally located in front of the nucleic acid to be expressed, but also by a promoter of the host cell provided on the expression vector or also by a modified or completely different promoter of another organism or another host cell.
- at least one promoter for the expression of a nucleic acid according to the invention is made available and used for its expression.
- expression vectors can be regulatable, for example by changing the culturing conditions or when a specific cell density of the host cells contained therein is reached or by addition of specific substances, in particular activators of gene expression.
- An example of such a substance is the galactose derivative isopropyl- ⁇ -D-thiogalactopyranoside (IPTG), which acts as activator of the bacterial lactose operon (lac- - -
- Operons is used. In contrast to expression vectors, the nucleic acid contained is not expressed in cloning vectors.
- a further subject of the invention is a non-human host cell which contains a nucleic acid according to the invention or a vector according to the invention or which contains a lipase according to the invention, in particular one which secretes the lipase into the medium surrounding the host cell.
- a nucleic acid according to the invention or a vector according to the invention is transformed into a microorganism, which then represents a host cell according to the invention.
- individual components, i. Nucleic acid parts or fragments of a nucleic acid according to the invention are introduced into a host cell such that the resulting host cell contains a nucleic acid according to the invention or a vector according to the invention.
- This procedure is particularly suitable when the host cell already contains one or more constituents of a nucleic acid according to the invention or a vector according to the invention and the further constituents are then supplemented accordingly.
- Methods of transforming cells are well established in the art and well known to those skilled in the art. In principle, all cells, that is to say prokaryotic or eukaryotic cells, are suitable as host cells. Preference is given to those host cells which can be handled genetically advantageously, for example as regards the transformation with the nucleic acid or the vector and its stable establishment, for example unicellular fungi or bacteria. Furthermore, preferred host cells are characterized by good microbiological and biotechnological handling.
- Preferred host cells according to the invention secrete the (transgenially) expressed protein into the medium surrounding the host cells.
- the lipases can be modified by the cells producing them after their production, for example by attachment of sugar molecules, formylations, aminations, etc. Such post-translational modifications can functionally influence the lipase.
- Further preferred embodiments are those host cells which are regulatable in their activity due to genetic regulatory elements which are provided, for example, on the vector, but may also be present in these cells from the outset. For example, by controlled addition of chemical compounds that serve as activators, by changing the culture conditions or when reaching a specific cell density, these can be excited for expression. This enables an economical production of the proteins according to the invention.
- An example of such a compound is IPTG as described above.
- Preferred host cells are prokaryotic or bacterial cells.
- Bacteria are characterized by short generation times and low demands on cultivation conditions. As a result, inexpensive cultivation methods or production methods can be established. moreover - The expert has a wealth of experience in bacteria in fermentation technology. For a specific production, gram-negative or gram-positive bacteria may be suitable for a wide variety of reasons to be determined experimentally in individual cases, such as nutrient sources, product formation rate, time requirement, etc.
- Gram-negative bacteria such as Escherichia coli
- Gram-negative bacteria can also be designed such that they eject the expressed proteins not only into the periplasmic space but into the medium surrounding the bacterium.
- gram-positive bacteria such as, for example, Bacilli or Actinomycetes or other representatives of the Actinomycetales
- gram-positive bacteria have no outer membrane, so that secreted proteins are readily released into the medium surrounding the bacteria, generally the nutrient medium, from which the expressed proteins can be purified. They can be isolated directly from the medium or further processed.
- Gram-positive bacteria are related or identical to most of the organisms of origin for technically important enzymes and usually form even comparable enzymes, so they have a similar codon use and their protein synthesizer is naturally aligned accordingly.
- Host cells according to the invention may be altered in their requirements of the culture conditions, have different or additional selection markers or express other or additional proteins. In particular, it may also be those host cells which express several proteins or enzymes transgene.
- the present invention is applicable in principle to all microorganisms, in particular to all fermentable microorganisms, particularly preferably those of the genus Bacillus, and results in the production of proteins according to the invention by the use of such microorganisms. Such microorganisms then represent host cells in the sense of the invention.
- the host cell is characterized in that it is a bacterium, preferably one selected from the genera Escherichia, Klebsiella, Bacillus, Staphylococcus, Corynebacterium, Arthrobacter, Streptomyces, Stenotrophomonas and Pseudomonas, more preferably one selected from the group of Escherichia coli, Klebsiella planticola, Bacillus licheniformis, Bacillus lentus, Bacillus amyloliquefaciens, Bacillus subtilis, Bacillus alcalophilus, Bacillus globigii, Bacillus gibsonii, Bacillus clausa, Bacillus halodurans, Bacillus pumilus, Staphylococcus carnosus, Corynebacterium glutamicum, Arthrobacter oxidans, Streptomyces lividans, Streptomyces coelicolor and Stenotrophomon
- the host cell may also be a eukaryotic cell, which is characterized in that it has a cell nucleus.
- a further subject of the invention therefore represents a host cell, which is characterized in that it has a cell nucleus.
- eukaryotic cells are capable of post-translationally modifying the protein formed. Examples thereof are fungi such as Actinomycetes or yeasts such as Saccharomyces or Kluyveromyces. This may be particularly advantageous, for example, if the proteins are to undergo specific modifications in the context of their synthesis that enable such systems.
- Modifications that eukaryotic systems perform, especially in connection with protein synthesis include, for example, the binding of low molecular weight compounds such as membrane anchors or oligosaccharides. Such oligosaccharide modifications may be desirable, for example, to lower the allergenicity of an expressed protein. Also, coexpression with the enzymes naturally produced by such cells, such as cellulases, may be advantageous. Furthermore, for example, thermophilic fungal expression systems may be particularly suitable for expressing temperature-resistant proteins or variants.
- the host cells according to the invention are cultured and fermented in the usual way, for example in discontinuous or continuous systems.
- a suitable nutrient medium is inoculated with the host cells and the product is harvested from the medium after an experimentally determined period of time.
- Continuous fermentations are characterized by achieving a flow equilibrium, in which over a relatively long period of time cells partly die out but also regrow and at the same time the protein formed can be removed from the medium.
- Host cells according to the invention are preferably used to prepare lipases according to the invention.
- Another object of the invention is therefore a method for producing a lipase comprising
- This subject invention preferably comprises fermentation processes. Fermentation processes are known per se from the prior art and represent the actual large-scale production step, usually followed by a suitable purification method of the product produced, for example the lipases according to the invention. All fermentation processes which are based on a corresponding process for preparing a lipase according to the invention represent embodiments of this subject matter of the invention.
- Fermentation processes which are characterized in that the fermentation is carried out via a feed strategy, come in particular into consideration.
- the media components consumed by the ongoing cultivation are fed. This allows - Significant increases in both the cell density and in the cell mass or dry matter and / or in particular in the activity of the lipase of interest are achieved.
- the fermentation can also be designed so that undesired metabolic products are filtered out or neutralized by the addition of buffer or suitable counterions.
- the produced lipase can be harvested from the fermentation medium.
- Such a fermentation process is resistant to isolation of the lipase from the host cell, i. however, requires the provision of suitable host cells or one or more suitable secretion markers or mechanisms and / or transport systems for the host cells to secrete the lipase into the fermentation medium.
- isolation of the lipase from the host cell i. a purification of the same from the cell mass, carried out, for example by precipitation with ammonium sulfate or ethanol, or by chromatographic purification.
- Another object of the invention is an agent which is characterized in that it contains a lipase according to the invention as described above.
- the agent is as a washing or cleaning agent.
- This subject matter of the invention includes all conceivable types of detergents or cleaners, both concentrates and undiluted agents, for use on a commercial scale, in the washing machine or in hand washing or cleaning.
- detergents for textiles, carpets, or natural fibers, for which the term detergent is used.
- the washing and cleaning agents in the invention also include laundry aids, which are added to the actual detergent in the manual or machine textile laundry to achieve a further effect.
- laundry detergents and cleaners in the context of the invention also include textile pre-treatment and post-treatment agents, ie those agents with which the laundry item is brought into contact before the actual laundry, for example to dissolve stubborn soiling, and also agents which are in one of the actual Textile laundry downstream step to give the laundry further desirable properties such as comfortable grip, crease resistance or low static charge.
- the fabric softeners are calculated. - -
- the washing or cleaning agents according to the invention may contain, in addition to a lipase according to the invention, all known ingredients customary in such agents, preferably at least one further ingredient being present in the composition .
- the agents according to the invention may contain, in particular, surfactants, builders, peroxygen compounds or bleach activators. In addition, they may contain water-miscible organic solvents, further enzymes, sequestering agents, electrolytes, pH regulators and / or further auxiliaries such as optical brighteners, grayness inhibitors, foam regulators, as well as dyes and fragrances, and combinations thereof.
- the detergents or cleaners are liquid, i. at room temperature and Normaldrucj (20 ° C and 1013 mbar) flowable.
- a combination of a lipase according to the invention with one or more further ingredients of the composition is advantageous, since in preferred embodiments according to the invention such an agent has an improved cleaning performance by virtue of resulting synergisms.
- a lipase according to the invention with a surfactant and / or a builder (builder) and / or a peroxygen compound and / or a bleach activator, such a synergism can be achieved.
- inventive ingredients of inventive compositions are disclosed in International Patent Application WO2009 / 121725, beginning on page 5, penultimate paragraph, and ending on page 13 after the second paragraph and WO2012084582 A1, pages 12-27.
- This disclosure is incorporated herein by reference and the disclosure is incorporated herein by reference.
- the lipases described herein may be advantageously combined with phosphonates as described in WO 2012084582 A1, page 4, second paragraph to page 5, first paragraph.
- An agent according to the invention advantageously contains the lipase in an amount of from 2 ⁇ g to 20 mg, preferably from 5 ⁇ g to 17.5 mg, more preferably from 20 ⁇ g to 15 mg and very particularly preferably from 50 ⁇ g to 10 mg per g of the composition.
- the lipase contained in the agent, and / or other ingredients of the agent may be coated with a substance impermeable to the enzyme at room temperature or in the absence of water which becomes permeable to the enzyme under conditions of use of the agent.
- Such an embodiment of the invention is thus characterized in that the lipase is coated with a substance which is impermeable to the lipase at room temperature or in the absence of water.
- the washing or cleaning agent itself may be packaged in a container, preferably an air-permeable container, from which it is released shortly before use or during the washing process.
- the agent is characterized in that it
- (A) is in solid form, in particular as a free-flowing powder having a bulk density of 300 g / l to 1200 g / l, in particular 500 g / l to 900 g / l, or
- (b) is in pasty or liquid form, and / or
- (c) is in the form of a gel or pouch, and / or
- (d) is present as a one-component system, or
- compositions according to the invention include all solid, powdered, liquid, gelatinous or paste-like administration forms of compositions according to the invention, which if appropriate can also consist of several phases and can be present in compressed or uncompressed form.
- the agent can be present as a free-flowing powder, in particular with a bulk density of 300 g / l to 1200 g / l, in particular 500 g / l to 900 g / l or 600 g / l to 850 g / l.
- the solid dosage forms of the composition also include extrudates, granules, tablets or pouches.
- the agent can also be liquid, gelatinous or pasty, for example in the form of a non-aqueous liquid detergent or a non-aqueous paste or in the form of an aqueous liquid detergent or a water-containing paste.
- the agents are liquid.
- the agent may be present as a one-component system. Such funds consist of one phase.
- an agent can also consist of several phases. Such an agent is therefore divided into several components.
- Detergents or cleaning agents according to the invention may contain only one lipase. Alternatively, they may also contain other hydrolytic enzymes or other enzymes in a concentration effective for the effectiveness of the agent. A further embodiment of the invention thus represents agents which further comprise one or more further enzymes.
- enzymes which can be used as further enzymes are all enzymes which can display catalytic activity in the agent according to the invention, in particular a protease, amylase, cellulase, hemicellulase, mannanase, tannase, xylanase, xanthanase, xyloglucanase, ⁇ -glucosidase, pectinase, carrageenase, Perhydrolase, oxidase, oxidoreductase or other - distinguishable from the lipases of the invention - lipases, and mixtures thereof.
- each additional enzyme is in an amount of 1 x 10 -3 ⁇ 7 wt .-%, of 0.00001-1 wt .-%, of 0.00005 to 0.5 wt .-%, from 0.0001 to 0, 1 wt .-% and particularly preferably from 0.0001 to 0.05 wt .-% in agents according to the invention, based on active protein.
- the enzymes show synergistic cleaning performance against certain stains or stains, ie the enzymes contained in the middle composition mutually support each other in their cleaning performance.
- a further subject of the invention is a process for the cleaning of textiles or hard surfaces, which is characterized in that an agent according to the invention is used in at least one process step or in at least one process step a lipase according to the invention becomes catalytically active, in particular such that the lipase in an amount of 4C ⁇ g to 4g, preferably from 5C ⁇ g to 3g, more preferably from 10C ⁇ g to 2g, and most preferably from 20C ⁇ g to 1g is used.
- the method described above is characterized in that the lipase at a temperature of 0-100, preferably 0-60 ° C, more preferably 20-40 ° C, most preferably 30-40 ° C or 32-40 ° C or about 40 ° C is used.
- Methods for cleaning textiles are generally distinguished by the fact that various cleaning-active substances are applied to the items to be cleaned and washed off after the contact time, or that the items to be cleaned are otherwise treated with a detergent or a solution or dilution of this product.
- All conceivable washing or cleaning processes can be enriched in at least one of the process steps by the use of a washing or cleaning agent or a lipase according to the invention and then represent embodiments of the present invention.
- All facts, objects and embodiments, the lipases according to the invention and containing them Means are described are also applicable to this subject invention. Therefore, reference is made at this point expressly to the disclosure in the appropriate place with the statement that this disclosure also applies to the above inventive method.
- a single and / or the sole step of such a method can consist in that the lipase as the only active-ingredient-active component is contacted with the soiling, preferably in a buffer solution or in water.
- Alternative embodiments of this subject matter of the invention are also processes for the treatment of textile raw materials or for textile care in which a lipase according to the invention becomes active in at least one process step. These include processes for textile raw materials, - -
- the invention also encompasses the use of the lipases described herein in detergents, for example as described above, for the (improved) removal of greasy soils, for example textiles or hard surfaces.
- the mature part of the lipase gene is mutagenized by means of error-prone mutagenesis according to known methods ("GeneMorph II Random Mutagenesis Kit” from Agilent).
- the mutant library is cloned by conventional methods into Pichia pastoris. The colonies are picked in 96 well deep-well plates and cultured for induction for an additional 72 h. After centrifugation, the supernatant is examined for lipase activity. Two consecutive error-prone rounds were performed, the first on the wild-type lipase, the second on the best-stabilized variant - - the first round (SEQ ID N0: 2). Furthermore, some mutants were created by targeted recombination, according to conventional methods.
- thermostability a microtiter plate-based assay using para-nitrophenol palmitate (p-NPP) as substrate was used. Upon enzymatic hydrolysis in the aqueous medium, para-nitrophenolate and palmitate were released, and then para-nitrophenolate was detected by absorbance measurement at a wavelength of 405 nm.
- P-NPP is used in the form of an emulsion, it is pre-dissolved in an aqueous buffer containing emulsifiers as Na-desoxycholate and alpha-olefinsulfonate (AOS).
- Sample buffer in which the lipase supernatants are diluted 225 mg / mL Brij35, 9 mM CaCl 2 and
- Substrate working buffer 96.7 mL emulsifier solution (100 mM Tris-HCl pH8.0, 6.5 mM deoxycholate, 1.4 g / L AOS) + 3.3 mL palmitate solution (7.8 mM p-NPP dissolved in ethanol )
- the lipase supernatants diluted in sample buffer were incubated both at 25 ° C and at a higher temperature for 40 min before the p-NPP assay was performed.
- the temperature was 32 ° C for the first Error Prone round and 37 ° C for the second Error Prone round in the screening, then 40 ° C for the Rescreening of the best hits.
- the factor is formed, activity after storage at elevated temp. Divided by activity after storage at 25 ° C. The higher this factor, the better the thermostability of the lipase variants in the detergent matrix.
- Liquid detergent matrix (commercially available, without enzymes, optical brightener, perfume and dyes), which was used for the activity test and washing test:
- Mutant 1 (starting clone; SEQ ID 0.26
- the enzymes are used in the same protein with 7.5 mg / washing machine
- the performance of the mutants is at least as good as that of the wild type, sometimes even better.
- the wild type shows no washing performance due to its instability.
- the washing temperature of the 60 minutes main wash was 40 ° C and 20 ° C.
- the detergent was dosed at 0.2 g in 50 mL water (16 ° dH).
- the experiment was carried out as a 5-fold determination. - -
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
L'invention concerne des lipases comprenant une séquence d'acides aminés présentant sur sa longueur totale une identité de séquence d'au moins 70 % avec la séquence d'acides aminés indiquée dans SEQ ID NO:1 et présentant une substitution d'acides aminés au moins dans une des positions S93, P145, L156, K169, N193, G202, Q225, K235, V236, P260, H298, P308, F311, N328, L352, D359 ou S364 respectivement par rapport à la numérotation selon SEQ ID NO:1. L'invention concerne également leur production et leur utilisation. Les lipases de ce type présentent une très haute stabilité, en particulier à la température, associée à de bonnes performances de purification.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017202034.2A DE102017202034A1 (de) | 2017-02-09 | 2017-02-09 | Lipasen mit erhöhter Thermostabilität |
| PCT/EP2018/052035 WO2018145927A1 (fr) | 2017-02-09 | 2018-01-29 | Lipases présentant une meilleure stabilité à la température |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3580335A1 true EP3580335A1 (fr) | 2019-12-18 |
Family
ID=61163690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18703258.6A Withdrawn EP3580335A1 (fr) | 2017-02-09 | 2018-01-29 | Lipases présentant une meilleure stabilité à la température |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20200002691A1 (fr) |
| EP (1) | EP3580335A1 (fr) |
| DE (1) | DE102017202034A1 (fr) |
| WO (1) | WO2018145927A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102016204813A1 (de) * | 2016-03-23 | 2017-09-28 | Henkel Ag & Co. Kgaa | Lipasen für den Einsatz in Wasch- und Reinigungsmitteln |
| EP3772540A1 (fr) | 2019-08-08 | 2021-02-10 | Henkel AG & Co. KGaA | Lipases à thermostabilité accrue |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2706778B2 (ja) | 1988-03-07 | 1998-01-28 | 天野製薬 株式会社 | 油脂の改質法 |
| EP0443063A1 (fr) | 1990-02-22 | 1991-08-28 | Henkel Research Corporation | Gène de la lipase de pseudomonas, vecteurs d'expression de ce gène, production de la lipase pour microorganismes transformés et utilisations de cet enzyme |
| WO2001038553A1 (fr) * | 1999-11-26 | 2001-05-31 | Kansai Chemical Engineering Co., Ltd. | Fabrication d'alcool ester inferieur d'acide gras |
| US10676751B2 (en) * | 2008-02-29 | 2020-06-09 | The Trustees Of The University Of Pennsylvania | Production and use of plant degrading materials |
| DE102008017103A1 (de) | 2008-04-02 | 2009-10-08 | Henkel Ag & Co. Kgaa | Wasch- und Reinigungsmittel enthaltend Proteasen aus Xanthomonas |
| DE102010063743A1 (de) | 2010-12-21 | 2012-06-21 | Henkel Ag & Co. Kgaa | Flüssige Tensidzubereitung enthaltend Lipase und Phosphonat |
| EP3149159B1 (fr) * | 2014-05-27 | 2018-11-14 | Novozymes A/S | Procédé de modification d'une lipase |
-
2017
- 2017-02-09 DE DE102017202034.2A patent/DE102017202034A1/de not_active Withdrawn
-
2018
- 2018-01-29 US US16/484,909 patent/US20200002691A1/en not_active Abandoned
- 2018-01-29 WO PCT/EP2018/052035 patent/WO2018145927A1/fr not_active Ceased
- 2018-01-29 EP EP18703258.6A patent/EP3580335A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE102017202034A1 (de) | 2018-08-09 |
| WO2018145927A1 (fr) | 2018-08-16 |
| US20200002691A1 (en) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3299457A1 (fr) | Nouvelle lipase | |
| EP3433360B1 (fr) | Protéases présentant une meilleure stabilité enzymatique dans les détergents | |
| EP3679131A1 (fr) | Variantes de protéases à performances améliorées | |
| EP3679132A1 (fr) | Variantes de protéase à performances améliorées | |
| EP3458583A1 (fr) | Protéases à performance améliorée | |
| EP3433359A1 (fr) | Performance de nettoyage améliorée sur des salissures sensibles aux protéines | |
| EP3433350B1 (fr) | Lipases utilise dans des agents de lavage et de nettoyage | |
| EP3387122A1 (fr) | Lipases présentant une meilleure stabilité à la température | |
| EP3580335A1 (fr) | Lipases présentant une meilleure stabilité à la température | |
| WO2017162711A1 (fr) | Formulation liquide contenant une lipase | |
| WO2017133974A1 (fr) | Performance de lavage améliorée grâce à une alpha-amylase de bacillus cereus | |
| EP3458580A1 (fr) | Performance de lavage améliorée grâce à une nouvelle alpha-amylase derhizoctonia solani | |
| EP3440203B1 (fr) | Nouvelle protéase à performance de lavage améliorée | |
| EP3772540A1 (fr) | Lipases à thermostabilité accrue | |
| WO2019101417A1 (fr) | Amylase et détergent ou produit de nettoyage contenant une telle amylase | |
| WO2019228877A1 (fr) | Performance de lavage améliorée grâce à une nouvelle alpha-amylase de fomitopsis pinicola (fpi) | |
| WO2017133973A1 (fr) | Performance de lavage améliorée grâce à une alpha-amylase de bacillus cereus | |
| EP3464577A1 (fr) | Nouvelles amylases | |
| DE102018208446A1 (de) | Verbesserte Waschleistung durch eine neue alpha-Amylase aus Fomes fomentarius (Ffo) | |
| DE102018208443A1 (de) | Verbesserte Waschleistung durch eine neue alpha-Amylase Irpex lacteus (IIa) | |
| DE102018208444A1 (de) | Verbesserte Waschleistung durch eine neue alpha-Amylase aus Trametes hirsuta (Thi) | |
| DE102017215631A1 (de) | Leistungsverbesserte Proteasevarianten II |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20190711 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20200721 |